๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope
NCT06710873CIED Infection, TYRX Absorbable Antibacterial Envelope
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
50
Guangzhou
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study
NCT06492538Angle-closure Glaucoma, Minimally Invasive Glaucoma Surgery, Goniosynechialysis, Goniotomy
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
300
Guangzhou
2023-12-01
Recruiting
Study on Deep Transcranial Magnetic Stimulation for Enhancing Insight
NCT06831877Impaired Insight
Shanghai Mental Health Center
Not applicable
138
Shanghai
2023-12-01
Recruiting
Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade
NCT06080880Nausea With Vomiting Chemotherapy-Induced
Hubei Cancer Hospital
Not applicable
98
Wuhan
2023-12-01
Recruiting
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
NCT05925452Active Systemic Juvenile Idiopathic Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xiโ€™an, Chengdu
2023-12-01
Recruiting
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
NCT07353216Multiple Sclerosis
Third Affiliated Hospital, Sun Yat-Sen University
Observational
80
Guangzhou
2023-12-01
By invitation
National Multicenter Registry for Pediatric End-Stage Heart Failure in China
NCT06927440Heart Failure, Children
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-12-01
Not yet open
An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm/Iliac Aneurysm Repair
NCT06162273Aortic Aneurysm, Abdominal, Iliac Aneurysm
RenJi Hospital
Observational
40
Shanghai
2023-12-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
Pathological Type๏ผŒGene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism
NCT06597630Primary Aldosteronism
Qifu Li
Observational
100
Chongqing
2023-12-01
Not yet open
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
NCT06142617Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
Peking Union Medical College Hospital
Phase 2
37
Beijing
2023-12-01
Recruiting
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia
NCT06157437Typical Atrial Flutter, Atrial Fibrillation (AF)
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
10
Beijing
2023-12-01
Recruiting
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer
NCT07328945Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
250
Shanghai
2023-12-01
Recruiting
Anti-CD38 Antibody Treating Evans Syndrome
NCT06014775Evan Syndrome, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
10
Tianjin
2023-12-01
Active, closed
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
NCT06673134Crohn Disease
Tongji Hospital
Observational
100
Wuhan
2023-12-01
Recruiting
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Shanxi Bethune Hospital
Not applicable
45
Taiyuan
2023-12-01
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
NCT06095141Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Fudan University
Phase 2/3
30
Shanghai
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
NCT06234007Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Wuhan
2023-12-01
Not yet open
The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble
NCT06116357Primary Hypertension
Jing Huang
Not applicable
200
Chongqing
2023-12-01
Recruiting
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
NCT06146946Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Not yet open
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
NCT06101966Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
Fujian Cancer Hospital
Observational
500
Fuzhou
2023-12-01
Not yet open
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
NCT06147375Immune Tolerance, Immunosuppression, Liver Transplant; Complications
Wei Gao
Not applicable
47
Tianjin
2023-12-01
Recruiting
EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
NCT06161987Acute Decompensated Heart Failure
Guangdong Provincial People's Hospital
Not applicable
140
Guangzhou
2023-12-01
Recruiting
Cancer of Esophagogastric Junction: Optimized Sweet Versus Ivor-Lewis
NCT06162767Esophagogastric Junction Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
240
Nanjing
2023-12-01
By invitation
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
NCT06281964Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 3
327
Guangzhou
2023-12-01
Active, closed
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NCT06246344Rectal Cancer
Shandong Cancer Hospital and Institute
Phase 3
128
Jinan
2023-12-01
Recruiting
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
NCT06177301Nasopharyngeal Carcinoma
Fudan University
Phase 3
266
Shanghai
2023-12-01
Active, closed
Study on the Efficacy of Probiotics in the Treatment of Childhood Obesity and Their Effects on Gut Microbiota
NCT07448220Overweight , Obesity
Min-Tze LIONG
Phase 2
60
Jiading
2023-12-01
Recruiting
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07266493Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
Sun Yat-sen University
Phase 2
71
Guangzhou
2023-12-01
Not yet open
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
NCT05965388HBV, HCC
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xiโ€™an
2023-12-01
Active, closed
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Haโ€™erbin, Jinan
2023-12-01
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
POEM-F for Achalasia International Study
NCT06042127Achalasia
Chinese University of Hong Kong
Not applicable
81
Guangzhou
2023-12-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Recruiting
Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer
NCT05990946Lung Neoplasms, Non-Small Cell Lung Cancer, Postoperative Complications, Patient Reported Outcome Measures, Telerehabilitation
Zhongshan People's Hospital, Guangdong, China
Not applicable
736
Zhongshan
2023-12-01
Recruiting
Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters
NCT06964867Vitreous Floaters, Anxiety
Changzhou No.2 People's Hospital
Not applicable
300
Changzhou
2023-12-01
Not yet open
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
NCT05979220Breast Cancer
Shuangyue Liu
Phase 2
178
Chengdu
2023-12-01
Recruiting
Evaluation of PWI Assisted by Marshall Ethanolization in Ablation of Persistent Atrial Fibrillation
NCT06363604Atrial Fibrillation
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
260
Shanghai
2023-12-01
Recruiting
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
NCT06829472Toxicities, Survivorship
Shanghai Jiao Tong University School of Medicine
Phase 3
120
Shanghai
2023-12-01
Recruiting
Efficacy of Internet-Based Cognitive Behavioral Therapy for Back Muscle Strength Loss, Chronic Pain, and Poor Patient Recovery Perceptions After Lumbar Fusion
NCT07030582Internet-Based Cognitive Behavioral Therapy
Jiawei Jiang
Not applicable
100
Nantong
2023-12-01
Active, closed
Rapid Abdominal Diagnosis With AI & Radiology
NCT07040358Abdominal Diseases
First Affiliated Hospital of Zhejiang University
Observational
2,000,000
Hangzhou
2023-12-01
Recruiting
An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy
NCT06151028Gynecological Malignancies, Menopausal Symptoms, Bone Loss
Anhui Provincial Hospital
Observational
490
Hefei
2023-12-01
Recruiting
Prevention of Insomnia Using a Stepped Care Model in Adults
NCT06156293Sleep Disturbance
Chinese University of Hong Kong
Not applicable
1,016
Hong Kong
2023-12-01
Recruiting
Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures
NCT06379243Osteoporosis Fracture, Osteoporosis Vertebral, Compression Fracture, Perform PVP / PKP Treatment
The Seventh Affiliated Hospital of Sun Yat-sen University
Not applicable
560
Guangzhou
2023-12-01
Not yet open
The Efficacy of Heparin-boned Viabahn Endoprosthesis and Paclitaxel-coated Balloons for Complex Femoropopliteal Lesions
NCT06124755Peripheral Arterial Disease
RenJi Hospital
Not applicable
60
Shanghai
2023-12-01
Recruiting
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
NCT05994274Heart Transplant Failure and Rejection
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
80
Wuhan
2023-12
Not yet open
Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
NCT06178432Pompe Disease (Late-onset)
Huashan Hospital
Phase EARLY_PHASE1
6
Shanghai
2023-12
Not yet open
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2
129
Jinan, Tianjin
2023-12
Not yet open
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
NCT06178211Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
36
Shanghai
2023-12
Not yet open
PET Imaging of 68Ga-NOTA-H006 in Malignancy
NCT06162988Tumor, Solid
YiHui Guan
Not applicable
15
Shanghai
2023-12
Recruiting
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Recruiting
Cohort of Nursing Homes
NCT07249086Health Status
Institute of Hematology & Blood Diseases Hospital, China
Observational
1,500
Tianjin
2023-11-30
Recruiting
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
NCT06010875Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
48
Nanchang
2023-11-30
Not yet open
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06149533Thrombosis, Venous, Cancer, Catheter Complications
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Active, closed
Endovascular Treatment of Cerebrovascular Diseases Guided by Optical Coherence Tomography (OCT) Technology๏ผˆCVD-OCT๏ผ‰
NCT06986330Carotid Stenosis, Optical Coherence Tomography (OCT), Endovascular Treatment
First Affiliated Hospital of Wannan Medical College
Observational
200
Wuhu
2023-11-30
Not yet open
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
NCT06140576Breast Neoplasms
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
Recruiting
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688CNS Lymphoma
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Recruiting
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
NCT06132698NSCLC Associated With Leptomeningeal Metastases
West China Hospital
Phase 2
17
Chengdu
2023-11-30
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Changsha, Nanchang, Shanghai
2023-11-29
By invitation
A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
NCT06160557Esophagus Cancer, Radiotherapy, Endoscopic Mucosal Resection
Xiaomeng Zheng
Observational
40
Fuzhou
2023-11-29
Recruiting
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
NCT06199895Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer
Liu Huang
Phase 2
25
Wuhan
2023-11-28
By invitation
Potential Biomarkers and Pathogenic Mechanism for Reflux Aspiration-induced Lung Injury.
NCT06164639ARDS, Human, Aspiration Pneumonia
Shanghai Zhongshan Hospital
Observational
28
Shanghai
2023-11-28
Recruiting
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
NCT06108492Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
170
Shanghai
2023-11-28
Recruiting
Application Evaluation Research on the Artificial Intelligence-assisted Support System for the Diagnosis of Colorectal Tubular Adenoma Lesions
NCT07073430Colorectal Adenoma, Artificial Intelligence (AI)
Renmin Hospital of Wuhan University
Observational
4,000
Wuhan
2023-11-28
Recruiting
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
NCT06347653Nodal T-follicular Helper Cell Lymphoma
Peking University
Phase 2
54
Beijing
2023-11-28
Recruiting
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
NCT06125405Nephrotic Syndrome in Children, Telitacicept
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
20
Hangzhou
2023-11-28
Recruiting
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
NCT06178159Breast Cancer
RemeGen Co., Ltd.
Phase 2
40
Shanghai
2023-11-28
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection
NCT06051513Carbapenem-Resistant Enterobacteriaceae Infection
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Active, closed
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891Unresectable Hepatocellular Carcinoma
Bayer
Observational
300
Multiple Locations
2023-11-27
Recruiting
Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients
NCT05924373Periodontitis
Peking University Third Hospital
Phase 2
204
Beijing
2023-11-27
By invitation
Study on the Sociopsychoemotional Mechanism of Dysfunction in Patients With Acute and Chronic Low Back Pain
NCT06684665Low Back Pain
Second Affiliated Hospital of Wenzhou Medical University
Observational
1,000
Wenzhou
2023-11-27
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors
NCT06132828Solid Tumor
Zhejiang Doer Biologics Co., Ltd.
Phase 1
216
Shanghai
2023-11-27
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
The Role of B7-H4 in Tumor Vaccine
NCT06156150Glioma
Huashan Hospital
Observational
160
Shanghai
2023-11-26
Recruiting
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05638867Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
China National Center for Cardiovascular Diseases
Phase 4
3,944
Beijing
2023-11-25
Recruiting
Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension
NCT03945305Essential Hypertension
Yi Yang
Not applicable
500
Changchun
2023-11-25
By invitation
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
NCT06115642Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech
Phase 1
367
Beijing, Changsha
2023-11-24
Recruiting
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
NCT06065046Traumatic Brain Injury
Tang-Du Hospital
Phase 2
100
Xi'an
2023-11-24
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Recruiting
Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
NCT06204406Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
RenJi Hospital
Observational
106
Shanghai
2023-11-23
Recruiting
A Clinical Trial of Parkinson's Disease Treatment by HiPSCs Derived Dopaminergic Neural Precursor Cells
NCT06145711Parkinson's Disease
Shanghai East Hospital
Not applicable
3
Shanghai
2023-11-23
Recruiting
Clinical Evaluation of Surrounding Electroacupuncture in the Treatment of Acute Lateral Ankle Sprain
NCT06182943Electroacupuncture
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
84
Hangzhou
2023-11-23
Recruiting
Research on the Development and Clinical Evaluation of Biomimetic Abutments
NCT06870955Tooth Loss
Stomatological Hospital Affiliated with Fujian Medical University
Not applicable
30
Fuzhou
2023-11-23
Recruiting
Cardiac Magnetic Resonance Monitoring of Immune Checkpoint Inhibitor-related Cardiotoxicity
NCT06132984Immune Checkpoint Inhibitors, Cardiotoxicity
West China Second University Hospital
Observational
22
Chengdu
2023-11-23
Recruiting
Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting
NCT06141525Coronary Artery Bypass Grafting, Remote Ischemic Conditioning, Ischemia-Reperfusion Injury
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
648
Xi'an
2023-11-22
Recruiting
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
NCT06151119Primary Myelofibrosis
The First Affiliated Hospital of Xiamen University
Observational
90
Xiamen
2023-11-22
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06151106Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
NCT06158412Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
The First Affiliated Hospital of Xiamen University
Phase 2
25
Xiamen
2023-11-22
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
NCT06158399DLBCL - Diffuse Large B Cell Lymphoma, TP53
The First Affiliated Hospital of Xiamen University
Phase 2
52
Xiamen
2023-11-22
Recruiting
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
NCT05888870Hemophilia A With Inhibitor
Institute of Hematology & Blood Diseases Hospital, China
Phase 4
50
Tianjin
2023-11-22
Recruiting
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
NCT06164561Myelofibrosis
First Affiliated Hospital of Zhejiang University
Observational
57
Hangzhou
2023-11-21
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Recruiting
Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis
NCT07802405MF With Splenomegaly
Henan Cancer Hospital
Phase 1
20
Zhengzhou
2023-11-21
Rows per page Showing 14201–14300 of 19052
Previous 141 142 143 144 145 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china?page=143

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.